Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Expenditures (2016 - 2025)

Neurocrine Biosciences' Capital Expenditures history spans 16 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 105.57% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $2.2 million, changed 0.0%, while the annual FY2025 figure was $2.2 million, 0.0% changed from the prior year.
  • Capital Expenditures reached $1.6 million in Q4 2025 per NBIX's latest filing, up from -$22.6 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $22.1 million in Q3 2023 to a low of -$28.7 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $1.3 million, with a median of $4.4 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: tumbled 4350.0% in 2021, then skyrocketed 5700.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $1.6 million in 2021, then skyrocketed by 887.5% to $15.8 million in 2022, then tumbled by 229.11% to -$20.4 million in 2023, then crashed by 40.69% to -$28.7 million in 2024, then skyrocketed by 105.57% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Capital Expenditures are $1.6 million (Q4 2025), -$22.6 million (Q3 2025), and $12.5 million (Q2 2025).